Deutsche Bank analyst Emmanuel Papadakis maintained a Buy rating on BioNTech SE (BNTX – Research Report) today and set a price target of ...
BioNTech SE (BNTX) has released an update. BioNTech SE reported a strong third quarter in 2024, with revenues reaching €1.2 ...
BNTX has been the topic of a number of recent analyst reports. UBS Group lifted their target price on BioNTech from $97.00 to $131.00 and gave the company a “neutral” rating in a research ...
In a report released today, Cory Kasimov from Evercore ISI maintained a Hold rating on BioNTech SE (BNTX – Research Report), with a price target of $110.00. The company’s shares closed yesterday at ...
Pfizer (PFE) stock fell even as the company beat forecasts with its Q3 results and increased its full-year outlook.Find out ...
FDA Presses Clinical Hold Button For BioNTech's Partner Late-Stage Trial Of Investigational Lung Cancer Treatment BioNTech's Phase 3 NSCLC trial is paused after varying outcomes. Current ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Pfizer (PFE) stock gained after the company beat estimates with its Q3 2024 financials and raised its full-year guidance ...
Below is Validea's guru fundamental report for BIONTECH SE - ADR (BNTX). Of the 22 guru strategies we follow, BNTX rates highest using our Value Investor model based on the published strategy of ...
BioNTech SE (BNTX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Yaron Werber ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback